Respiratory · AsthmaTrial Updatecompetitivemid-term

GRANITE Study Evaluates Airsupra vs Albuterol for Asthma Exacerbation Risk

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/31/2026, 6:32:21 AM

Assessment confidence: 53% · The main uncertainty is limited high-relevance corpus coverage for this sub-indication.

Executive Thesis

The GRANITE study's results could significantly influence the competitive landscape for asthma treatments, particularly between Airsupra and established therapies like albuterol. Positive findings may lead to increased adoption of Airsupra, impacting market dynamics and positioning. Regulatory context from MHRA (MHRA approves world's first lower-carbon beclometasone inhalers for patients with asthma) supports the near-term read. Assessment grounded in 7 ranked evidence items (2 high-relevance).

Strategic Assessment

Positive outcomes may enhance Airsupra's adoption and market share in asthma management. The strongest clinical anchor is Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76) (ClinicalTrials.gov), sponsor/company relevance (novartis). In asthma, 2 regulatory and 3 competitive items passed relevance filtering for Airsupra.

Competitive Pressure

The most relevant competitive pressure comes from [Ad hoc announcement pursuant to Art. (Roche) — sponsor/company relevance (roche). Secondary pressure from [Ad hoc announcement pursuant to Art.. Results could impact the market positioning of Airsupra against established treatments like albuterol.

Regulatory Outlook

Regulatory risk is concentrated around MHRA approves world's first lower-carbon beclometasone inhalers for patients with asthma (MHRA). Sub-indication match (asthma). Relevant agencies in corpus: MHRA, FDA. The study's outcomes are unlikely to affect regulatory approvals or compliance, as both drugs are already on the market. However, they may influence future labeling claims.

Key Opportunities

If Airsupra demonstrates superior efficacy, it could capture a larger market share, affecting revenue streams for both Airsupra and albuterol. This shift may alter competitive positioning in the asthma treatment market.
Positive outcomes may enhance Airsupra's adoption and market share in asthma management.

What Would Change This Assessment

This becomes more urgent if Monitor results from the GRANITE study for efficacy data and subsequent market reactions.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

MHRA approves world's first lower-carbon beclometasone inhalers for patients with asthma
MHRAhigh relevance
Sub-indication match (asthma)
FDA document
View source
FDA AP — ALBUTEROL SULFATE (ORIG)
FDAmedium relevance
Entity match (albuterol); Regulatory pathway relevance (nda)
FDA document
View source
Cancer Clinical Trial Eligibility Criteria: Laboratory Values
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Cancer Clinical Trial Eligibility Criteria: Washout Periods and Concomitant Medications
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
ClinicalTrials.govmedium relevance
Sponsor/company relevance (Novartis)
FDA document
View source
A Clinical Trial to Assess the Effect of AP-Brain Collagen Peptides on the Improvement of Attention, Focus, and Memory in Stressed But Otherwise Healthy Individuals
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
A Clinical Trial to Evaluate the Effects of the Edge+Ease PM+AM System on Mood, Mental Clarity, Sleep Quality, and Digestive Wellbeing
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
A Clinical Trial to Investigate the Efficacy and Safety of Plant-derived Cetylated Fatty Acids (CFA) on Knee Pain and Stiffness in Healthy Adults With Persistent Knee Pain
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

[Ad hoc announcement pursuant to Art.
Rochemedium relevance
Sponsor/company relevance (Roche)
FDA document
View source
[Ad hoc announcement pursuant to Art.
Rochemedium relevance
Sponsor/company relevance (Roche)
FDA document
View source
[Ad hoc announcement pursuant to Art.
Rochemedium relevance
Sponsor/company relevance (Roche)
FDA document
View source
Mobile App-Delivered ACT Shows Efficacy in PTSD Treatment in China
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities

Aerobic training versus behavioural intervention to increase physical activity on clinical control of people with moderate-to-severe asthma: A randomised clinical trial.
PubMedhigh relevance
Sub-indication match (asthma)
FDA document
View source
High-flow nasal cannula oxygenation in sedated endoscopy for high-risk obstructive sleep apnea patients: study protocol for a multicentre randomised controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Real-world effectiveness of HPV vaccination against high-risk type HPV DNA positivity among adult women aged 18 - 45years in China: A matched test-negative design study.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Amino acid infusion and acute kidney injury after aortic surgery: a multicenter observational study with target trial emulation.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Neoadjuvant immunochemotherapy and postoperative acute hypoxemic respiratory failure in thoracic surgery: a multicentre cohort study.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
The effects of sexual counseling based on the EX-PLISSIT and BETTER models on female sexual function after assisted reproductive treatment failure: a randomized clinical trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Airsupra
Albuterol
clinical stakeholders

Commercial impact

medium

If Airsupra demonstrates superior efficacy, it could capture a larger market share, affecting revenue streams for both Airsupra and albuterol. This shift may alter competitive positioning in the asthma treatment market.

Regulatory impact

low

The study's outcomes are unlikely to affect regulatory approvals or compliance, as both drugs are already on the market. However, they may influence future labeling claims.

What to watch

Monitor results from the GRANITE study for efficacy data and subsequent market reactions.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.